The resurgence of tuberculosis and the surge of multidrug-resistant clinical isolates of Mycobacterium tuberculosis have reaffirmed tuberculosis as a primary public health concern. In this review we describe some new findings on the pharmacological status of fluoroquinolones derivatives (Gatifloxacin, Moxifloxacin and Sitafloxacin), new macrolides (Clarithromycin, Azithromycin and Roxithromycin), new rifamycin derivatives (Rifapentin, Rifabutin and Rifalazil) and new oxazolidinones (Linezolid and PNU 100480). We describe also other type of agents that are being developed as antimycobacterial drugs. Some of these are under clinical investigation, while others are considered to be promising candidates for future development. Among them, nitroimidazopyrans, new ketolides, Isoxyl (ISO), pyrroles derived from BM 212, Mefloquine and Diarylquinoline R207910 are discussed. We also describe the mechanism of drug resistance in mycobacteria, as well as new potential targets. © 2006 Bentham Science Publishers Ltd.

New trends in development of antimycobacterial compounds / Biava, Mariangela; Porretta, Giulio Cesare; D., Deidda; R., Pompei. - In: INFECTIOUS DISORDERS - DRUG TARGETS. - ISSN 1871-5265. - STAMPA. - 6:2(2006), pp. 159-172. [10.2174/187152606784112173]

New trends in development of antimycobacterial compounds

BIAVA, Mariangela;PORRETTA, Giulio Cesare;
2006

Abstract

The resurgence of tuberculosis and the surge of multidrug-resistant clinical isolates of Mycobacterium tuberculosis have reaffirmed tuberculosis as a primary public health concern. In this review we describe some new findings on the pharmacological status of fluoroquinolones derivatives (Gatifloxacin, Moxifloxacin and Sitafloxacin), new macrolides (Clarithromycin, Azithromycin and Roxithromycin), new rifamycin derivatives (Rifapentin, Rifabutin and Rifalazil) and new oxazolidinones (Linezolid and PNU 100480). We describe also other type of agents that are being developed as antimycobacterial drugs. Some of these are under clinical investigation, while others are considered to be promising candidates for future development. Among them, nitroimidazopyrans, new ketolides, Isoxyl (ISO), pyrroles derived from BM 212, Mefloquine and Diarylquinoline R207910 are discussed. We also describe the mechanism of drug resistance in mycobacteria, as well as new potential targets. © 2006 Bentham Science Publishers Ltd.
2006
anti-tb therapy; drug-combinations; drug-resistance; mycobacterium avium complex; mycobacterium tuberculosis; new targets; promising drugs; tuberculosis
01 Pubblicazione su rivista::01a Articolo in rivista
New trends in development of antimycobacterial compounds / Biava, Mariangela; Porretta, Giulio Cesare; D., Deidda; R., Pompei. - In: INFECTIOUS DISORDERS - DRUG TARGETS. - ISSN 1871-5265. - STAMPA. - 6:2(2006), pp. 159-172. [10.2174/187152606784112173]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/121310
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 22
  • ???jsp.display-item.citation.isi??? ND
social impact